Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
Expert Ratings for Haemonetics
Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Mizuho Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $90
Mizuho analyst Anthony Petrone initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and announces Price Target of $90.
Important Biotech Catalysts For September 12, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…
Where Haemonetics Stands With Analysts
Within the last quarter, Haemonetics (NYSE:HAE) has observed the following analyst ratings:
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $88
Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $76 to $88.
Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
Raymond James Thinks Haemonetics Growth Is ‘Underappreciated’
Earlier this week, Raymond James attended Haemonetics Corp’s (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including…
Morgan Stanley Maintains Equal-Weight Rating for Haemonetics: Here’s What You Need To Know
Morgan Stanley has decided to maintain its Equal-Weight rating of Haemonetics (NYSE:HAE) and raise its price target from $60.00 to $70.00.
Shares of Haemonetics are trading up 1.46% over the last 24 hours, at $66.13 per share.
A move to $70.00 would account for a 5.85% increase from the current share price.
Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70
Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.